Study of AZD4512 for adults and teens with relapsed B-ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new drug called AZD4512, alone or with other cancer drugs, for people whose B-ALL has come back or did not respond to treatment. It may be an option if you have tried at least 2 prior therapies or have no standard options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old (or 18 if in the US for the first part of the study).
- You have a type of B-ALL that has returned or is not responding to treatment, and your leukemia cells have a protein called CD22.
- You have tried at least 2 prior treatments that didn't work, or 1 prior treatment and no other standard options are available.
- Your level of leukemia cells in the blood must be low enough (less than 10,000 per microliter) before starting treatment.
- You must have a good ability to perform daily activities (ECOG score of 0-2 or Karnofsky/Lansky score of at least 50).
- You must wait at least 4 weeks after certain prior treatments like cell therapy or stem cell transplant before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This trial tests a new drug called AZD3470, given alone or with other cancer treatments, for people with certain types of lymphoma (Hodgkin's lymphoma or T-cell lymphoma). It aims to see if the drug is safe and effective for patients who have already tried other treatments.
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
This Phase 2 study tests a treatment approach for children with high-risk ALL that has returned. It aims to improve outcomes after relapse by using a planned treatment schedule.
This Phase 1/2 study tests a type of immune therapy (CAR-T cells) made to recognize CD19 and CD22, two markers on B-ALL cells. It is for children and adults with B-ALL that has come back or did not respond to standard treatments, aiming to improve outcomes when other options have failed.
Hear when a new B-cell Acute Lymphoblastic Leukemia (B-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.